Alder BioPharma (ALDR) Misses Q1 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. CDNS
2. AVGO
3. SPY
4. META
5. JBLU
6. ANT
7. AAPL
8. SSD
9. ARTV
10. AGYS

Go back to Alder BioPharma (ALDR) Misses Q1 EPS by 4c

Alder BioPharmaceuticals Reports First Quarter 2016 Financial and Operating Results

April 28, 2016 4:10 PM EDT

BOTHELL, Wash., April 28, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today provided a corporate update and reported its financial results for the first quarter ended March 31, 2016.

Since we set forth our accelerated development program last year, we continue to leverage our positive clinical data to advance ALD403 for migraine prevention, said Randall C. Schatzman, Ph.D., president and chief executive officer of Alder. Our clinical trial results to date continue to support ALD403 as a potential best-in-class therapeutic with robust and immediate migraine... More